The ONL difference

ONL is the first and only company focused on preventing the death of key retinal cells, including photoreceptors—the root cause of vision loss and the leading cause of blindness. The company is advancing programs that address retinal diseases and conditions, including retinal detachment and both the wet and dry forms of age-related macular degeneration (AMD).


ONL1204, the company’s lead therapeutic candidate, is a first-in-class small molecule peptide designed to inhibit the death of key retinal cells, including photoreceptors, that occurs in a range of retinal diseases and conditions.

Contact Us

Start typing and press Enter to search